WO2022240143A1 - 발암성 돌연변이 유전자 검출용 가이드 rna 내지 이의 용도 - Google Patents
발암성 돌연변이 유전자 검출용 가이드 rna 내지 이의 용도 Download PDFInfo
- Publication number
- WO2022240143A1 WO2022240143A1 PCT/KR2022/006665 KR2022006665W WO2022240143A1 WO 2022240143 A1 WO2022240143 A1 WO 2022240143A1 KR 2022006665 W KR2022006665 W KR 2022006665W WO 2022240143 A1 WO2022240143 A1 WO 2022240143A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- guide rna
- seq
- wild
- mutation
- cancer
- Prior art date
Links
- 108020005004 Guide RNA Proteins 0.000 title claims abstract description 205
- 108090000623 proteins and genes Proteins 0.000 title abstract description 31
- 231100000590 oncogenic Toxicity 0.000 title abstract description 22
- 230000002246 oncogenic effect Effects 0.000 title abstract description 22
- 230000035772 mutation Effects 0.000 claims abstract description 154
- 108091033409 CRISPR Proteins 0.000 claims abstract description 67
- 108020004414 DNA Proteins 0.000 claims abstract description 58
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 53
- 201000011510 cancer Diseases 0.000 claims abstract description 37
- 238000010354 CRISPR gene editing Methods 0.000 claims abstract 5
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 65
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 65
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 65
- 239000002773 nucleotide Substances 0.000 claims description 48
- 125000003729 nucleotide group Chemical group 0.000 claims description 48
- 239000000203 mixture Substances 0.000 claims description 21
- 102100030708 GTPase KRas Human genes 0.000 claims description 17
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 17
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 12
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims description 12
- 238000004393 prognosis Methods 0.000 claims description 11
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 9
- -1 MET Proteins 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 206010069755 K-ras gene mutation Diseases 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000005787 hematologic cancer Diseases 0.000 claims description 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 claims 3
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 115
- 238000003776 cleavage reaction Methods 0.000 description 59
- 230000007017 scission Effects 0.000 description 59
- 238000000338 in vitro Methods 0.000 description 52
- 238000004458 analytical method Methods 0.000 description 45
- 239000000523 sample Substances 0.000 description 20
- 108700028369 Alleles Proteins 0.000 description 18
- 238000003556 assay Methods 0.000 description 15
- 239000013612 plasmid Substances 0.000 description 14
- 102200055464 rs113488022 Human genes 0.000 description 14
- 102200085641 rs121913273 Human genes 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- 102200048955 rs121434569 Human genes 0.000 description 10
- 238000001514 detection method Methods 0.000 description 9
- 101710163270 Nuclease Proteins 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 239000004114 Ammonium polyphosphate Substances 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 101000910035 Streptococcus pyogenes serotype M1 CRISPR-associated endonuclease Cas9/Csn1 Proteins 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000011304 droplet digital PCR Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000013610 patient sample Substances 0.000 description 4
- 102220085771 rs121913237 Human genes 0.000 description 4
- 206010069754 Acquired gene mutation Diseases 0.000 description 3
- 108010042407 Endonucleases Proteins 0.000 description 3
- 102000004533 Endonucleases Human genes 0.000 description 3
- 206010064571 Gene mutation Diseases 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000011528 liquid biopsy Methods 0.000 description 3
- 230000037439 somatic mutation Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 238000010453 CRISPR/Cas method Methods 0.000 description 2
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000010201 enrichment analysis Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 230000000869 mutational effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 101150105382 MET gene Proteins 0.000 description 1
- 101100091501 Mus musculus Ros1 gene Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000012350 deep sequencing Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 238000009377 nuclear transmutation Methods 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 102200124923 rs121913254 Human genes 0.000 description 1
- 102220323292 rs747073805 Human genes 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000011521 systemic chemotherapy Methods 0.000 description 1
- 239000000107 tumor biomarker Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- the present invention relates to a guide RNA used for detecting an oncogenic mutant gene by cleaving a wild-type cancer cell gene using a CRISPR/Cas9 system or a use thereof.
- COSMIC Catalogue of Somatic Mutations in Cancer
- liquid biopsy has recently emerged as a useful alternative to conventional tissue biopsy, providing a non-invasive approach to detect and monitor tumor-derived elements circulating in the bloodstream, directly or indirectly as a source of cancer biomarkers.
- Blood contains two types of cancer-derived components that are susceptible to detailed molecular analysis.
- One is intact circulating tumor cells (CTCs) and cell-free circulating tumor DNA (cfDNA or circulating tumor DNA; ctDNA).
- CTCs circulating tumor cells
- cfDNA or circulating tumor DNA circulating tumor DNA
- This liquid biopsy helps analyze the DNA that the tumor normally releases into the bloodstream.
- the amount of cfDNA released into the bloodstream varies from 0.01% to 90% of all DNA present in plasma.
- liquid biopsy provides a large-scale, non-invasive approach to tumor molecular profiling without obtaining tumor tissue.
- CRISPR Clustered regular interspaced short palindromic repeats
- Cas CRISPR-associated protein systems
- CRISPR endonucleases e.g., type II Cas9 or type V Cpf1 recognize a protospacer-adjacent motif (PAM) downstream or upstream, respectively, of the target DNA sequence corresponding to the guide RNA (gRNA), resulting in duplication in the target DNA. induces strand breakage.
- PAM protospacer-adjacent motif
- gRNA guide RNA
- gRNA guide RNA
- Tumor-specific versus wild-type alleles can be enriched by specifically cleaving the wild-type DNA.
- RNA To cleave the wild-type target DNA using Cas9-sgRNA, a single guide RNA must be designed to target the sequence of the PAM site. However, since the DNA PAM site targeted in cfDNA is destroyed by oncogenic mutation, it is difficult to detect because it is not recognized by CRISPR endonuclease.
- CRISPR/Cas9 CRISPR endonuclease and Cas9
- the present invention was completed by preparing a guide RNA capable of specifically cleaving only wild-type DNA, not DNA.
- an object of the present invention is to provide a guide RNA of the CRISPR/Cas9 system or a composition or kit for diagnosing cancer or predicting prognosis containing the guide RNA.
- Another object of the present invention is to provide a method for providing information for cancer diagnosis or prognosis prediction, which includes the step of processing a patient's sample with guide RNA of the CRISPR/Cas9 system.
- the present invention is a guide RNA used in the CRISPR / Cas9 system,
- the guide RNA is characterized by cleaving wild-type cell-free DNA.
- the guide RNA may include one or more nucleotide sequences selected from the group consisting of SEQ ID NOs: 1 to 17.
- the guide RNA is a conversion mutation in any one or more regions selected from the group consisting of a trunk region, a semi-seed region, and a seed region of the guide RNA (transversion mutation) may have occurred.
- the guide RNA may include one or more nucleotide sequences selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 9, and SEQ ID NO: 13.
- the guide RNA may detect one or more cancer-related mutations selected from the group consisting of EGFR, MET, KRAS, PIK3CA, and BRAF.
- the guide RNA when detecting the EGFR mutation, should include any one or more nucleotide sequences selected from the group consisting of SEQ ID NOs: 1 to 4, 8, 9, and 11 to 13 can
- the guide RNA when detecting the MET mutation, may include one or more nucleotide sequences selected from the group consisting of SEQ ID NOs: 5 to 7.
- the guide RNA when detecting the KRAS mutation, may include the nucleotide sequence of SEQ ID NO: 10.
- the guide RNA when detecting the PIK3CA mutation, may include one or more nucleotide sequences selected from the group consisting of SEQ ID NOs: 14 to 16.
- the guide RNA when detecting the BRAF mutation, may include the nucleotide sequence of SEQ ID NO: 17.
- the present invention provides a composition for diagnosing cancer or predicting prognosis, comprising a CRISPR/Cas9 guide RNA comprising any one or more nucleotide sequences selected from the group consisting of SEQ ID NOs: 1 to 17.
- the guide RNA is a conversion mutation in any one or more regions selected from the group consisting of a trunk region, a semi-seed region, and a seed region of the guide RNA (transversion mutation) may have occurred.
- the guide RNA may detect one or more cancer-related mutations selected from the group consisting of EGFR, MET, KRAS, PIK3CA, and BRAF.
- the guide RNA may cleave wild-type cell-free DNA.
- the cancer is any one or more selected from the group consisting of lung cancer, pancreatic cancer, colon cancer, stomach cancer, breast cancer, kidney cancer, liver cancer, blood cancer, bladder cancer, and uterine cancer. It could be cancer.
- the present invention also provides a kit for diagnosing cancer or predicting prognosis comprising the composition.
- the present invention also provides a method for providing information for diagnosing cancer or predicting prognosis, comprising the step of treating a sample of a patient with the composition.
- the detection of oncogenic mutant genes using cell-free DNA with the existing CRISPR/Cas9 system targets mutations in three PAM sequence (NGG) nucleotides and has a low probability of detecting them with guide RNA.
- NGS PAM sequence
- the guide RNA of the present invention targets and cleave wild-type cell-free DNA, not the oncogenic mutant gene, through the CRISPR/Cas 9 system, and in particular, conversion mutations in the trunk region of the guide RNA It is possible to selectively target and amplify only oncogenic mutant genes by using a guide RNA that causes transversion mutation.
- the present invention is a guide RNA used in the CRISPR/Cas9 system, and the guide RNA may cleave wild-type cell-free DNA.
- the 'CRISPR/Cas 9 system' means that an enzyme capable of recognizing a specific nucleotide sequence called Cas9 and cutting a gene recognizes a single-stranded guide RNA (sgRNA) containing the nucleotide sequence and cuts a specific DNA.
- sgRNA single-stranded guide RNA
- the CRISPR/Cas9 system consists of sgRNA designed to accurately recognize target DNA and Cas9 that can cut target DNA based on it. Cas9 that recognizes the sgRNA cuts the DNA double helix.
- the guide RNA may include one or more nucleotide sequences selected from the group consisting of SEQ ID NOs: 1 to 17.
- Guide RNA containing the nucleotide sequence of SEQ ID NO: 1 is a wild-type guide RNA (wild sgRNA) capable of detecting EGFR (p.T790M) mutation, and SEQ ID NO: 18 can be used as a target sequence when used for in vitro cleavage analysis have.
- wild sgRNA wild-type guide RNA
- p.T790M EGFR
- Guide RNA containing the nucleotide sequence of SEQ ID NO: 2 is a transversion guide RNA (transversion sgRNA) capable of detecting EGFR (p.T790M) mutation, and when used for in vitro cleavage analysis, SEQ ID NO: 19 can be used as a target sequence.
- transversion sgRNA transversion guide RNA
- SEQ ID NO: 19 can be used as a target sequence.
- the mutant sequence can be amplified by 1% to 32%.
- Guide RNA containing the nucleotide sequence of SEQ ID NO: 3 is a wild-type guide RNA (wild sgRNA) capable of detecting EGFR (p.C797S) mutation, and SEQ ID NO: 20 can be used as a target sequence when used for in vitro cleavage analysis have.
- wild sgRNA wild-type guide RNA
- SEQ ID NO: 20 can be used as a target sequence when used for in vitro cleavage analysis have.
- the guide RNA containing the nucleotide sequence of SEQ ID NO: 4 is a transversion guide RNA (transversion sgRNA) capable of detecting EGFR (p.C797S) mutation, and SEQ ID NO: 21 is the target sequence when used for in vitro cleavage analysis.
- transversion sgRNA transversion guide RNA
- SEQ ID NO: 21 is the target sequence when used for in vitro cleavage analysis.
- Guide RNA containing the nucleotide sequence of SEQ ID NO: 5 is a wild-type guide RNA (wild sgRNA) capable of detecting MET c.2888 Int13-Exon14 Acceptor (Exon-14 Skipping) mutation, and when used for in vitro cleavage analysis, the sequence Number 22 or 23 can be used as a target sequence.
- wild sgRNA wild-type guide RNA
- Guide RNA containing the nucleotide sequence of SEQ ID NO: 6 is a wild-type guide RNA (wild sgRNA) capable of detecting MET c.3028 Exon14-Int14 Donor (Exon-14 Skipping) mutation, and when used for in vitro cleavage analysis, the sequence Number 24 or 25 can be used as a target sequence.
- wild sgRNA wild-type guide RNA
- Guide RNA containing the nucleotide sequence of SEQ ID NO: 7 is a wild-type guide RNA (wild sgRNA) capable of detecting MET 'TAC' Y1003X (Exon-14 Skipping) mutation, and when used for in vitro cleavage analysis, SEQ ID NO: 26 or 27 can be used as a target sequence.
- wild sgRNA wild-type guide RNA
- MET 'TAC' Y1003X Exon-14 Skipping
- the guide RNA containing the nucleotide sequence of SEQ ID NO: 8 is a wild-type guide RNA (wild sgRNA) capable of detecting EGFR (L718Q) mutation, and SEQ ID NO: 28 can be used as a target sequence when used for in vitro cleavage analysis.
- wild sgRNA wild-type guide RNA capable of detecting EGFR (L718Q) mutation
- Guide RNA containing the nucleotide sequence of SEQ ID NO: 9 is a transversion guide RNA (transversion sgRNA) capable of detecting EGFR (L718Q) mutation, and SEQ ID NO: 29 can be used as a target sequence when used for in vitro cleavage analysis. .
- transversion sgRNA transversion guide RNA
- SEQ ID NO: 29 can be used as a target sequence when used for in vitro cleavage analysis.
- the mutant sequence can be amplified from 0.8% to 23.7%.
- the guide RNA containing the nucleotide sequence of SEQ ID NO: 10 is a wild-type guide RNA (wild sgRNA) capable of detecting KRAS (c.35G) mutation, and SEQ ID NO: 30 or 31 is used as the target sequence when used for in vitro cleavage analysis. can do.
- wild sgRNA wild-type guide RNA
- SEQ ID NO: 30 or 31 is used as the target sequence when used for in vitro cleavage analysis. can do.
- the mutant sequence can be amplified by 1.5% to 50%.
- Guide RNA containing the nucleotide sequence of SEQ ID NO: 11 is a wild-type guide RNA (wild sgRNA) capable of detecting EGFR, 15 bp Del p. (729_761) mutation, and SEQ ID NO: 32 or 33 when used for in vitro cleavage analysis
- a target sequence can be used.
- the mutant sequence can be amplified from 0.5% to 23%.
- Guide RNA containing the nucleotide sequence of SEQ ID NO: 12 is a wild-type guide RNA (wild sgRNA) capable of detecting EGFR (p.L858R) mutation, and SEQ ID NO: 34 can be used as a target sequence when used for in vitro cleavage analysis have.
- wild sgRNA wild-type guide RNA
- SEQ ID NO: 34 can be used as a target sequence when used for in vitro cleavage analysis have.
- the guide RNA containing the nucleotide sequence of SEQ ID NO: 13 is a transversion guide RNA (transversion sgRNA) capable of detecting EGFR (p.L858R) mutation, and SEQ ID NO: 35 is the target sequence when used for in vitro cleavage analysis.
- transversion sgRNA transversion guide RNA
- SEQ ID NO: 35 is the target sequence when used for in vitro cleavage analysis.
- the guide RNA comprising the nucleotide sequence of SEQ ID NO: 14 is a wild-type guide RNA (wild sgRNA) capable of detecting PIK3CA (p.E542K or c.1624G>A) mutation, and SEQ ID NO: 36 when used for in vitro cleavage analysis. Or 37 can be used as a target sequence.
- wild sgRNA wild-type guide RNA
- SEQ ID NO: 36 when used for in vitro cleavage analysis.
- Or 37 can be used as a target sequence.
- Guide RNA containing the nucleotide sequence of SEQ ID NO: 15 is a wild-type guide RNA (wild sgRNA) capable of detecting PIK3CA (p.E545? or c.1633G>?) mutation, and when used for in vitro cleavage analysis, SEQ ID NO: 38 or 39 can be used as a target sequence.
- wild sgRNA wild-type guide RNA
- Guide RNA containing the nucleotide sequence of SEQ ID NO: 16 is a wild-type guide RNA (wild sgRNA) capable of detecting PIK3CA (p.H1047? or c.3140A>?) mutation, and when used for in vitro cleavage analysis, SEQ ID NO: 40 or 41 can be used as a target sequence.
- wild sgRNA wild-type guide RNA
- the guide RNA comprising the nucleotide sequence of SEQ ID NO: 17 is a wild-type guide RNA (wild sgRNA) capable of detecting PIK3CA (p.V600E or c.1799T>A) mutation, and SEQ ID NO: 42 when used for in vitro cleavage analysis. Or 43 can be used as a target sequence.
- wild sgRNA wild-type guide RNA
- SEQ ID NO: 42 when used for in vitro cleavage analysis.
- 43 can be used as a target sequence.
- the guide RNA is characterized in that a transversion mutation has occurred in one or more regions selected from the group consisting of a trunk region, a semi-seed region, and a seed region of the guide RNA guide RNA.
- Targeting DNA cleavage with SpCas9 mainly requires a specific 20 nucleotides of the target protospacer sequence along with 3 PAM sequence (NGG) nucleotides adjacent to the 3′ end of the target sequence. Mutations within the PAM sequence (caused by either mismatched PAM-NGN or any oncogenic mutation) cause Cas9 to cut from cell-free DNA to the wild-type target allele (PAM-NGG) to enrich for the mutant allele in wild-type DNA. Easy is the best candidate. However, it is not possible to have such discordant PAM target sequences for all cancer-associated mutations.
- the present inventors have prepared a transversion mutation (purine to pyrimidine) in the trunk region of guide RNA to solve the above problems and target all kinds of mutations.
- a transversion mutation purine to pyrimidine
- single base mismatches in guide RNA are classified into semi-seed, seed, trunk, and promiscuous regions.
- the guide RNA resistance to a single base mismatch within the seed region from position 4 to 7 is the lowest resistance of the corresponding sgRNA.
- both sides of the seed region at positions 1-3 and 8-11 are medium tolerance for mismatches and are defined as semi-seed regions.
- a single base mismatch at positions 12–19 reduced the cleavage frequency to an intermediate level but retained sgRNA activity and this intermediate region is termed the trunk region.
- a single base mismatch slightly reduces the frequency of cleavage induced by the Cas9 nuclease and this position is termed a multiple region.
- the Cas9 nuclease can be treated with transversion mutation guide RNA to enrich for the low-frequency mutant allele, followed by PCR amplification to remove the wild-type target allele. Mutant target alleles are not recognized or cleaved by the Cas9 nuclease. This is because of the low resistance to two mutations, one is a conversion mutation in the sgRNA and the second is a target mutation of the oncogenic mutation (Fig. 3a, Fig. 3b).
- the Cas9 nuclease may include various variants and may be Cas9, eCas9 or HFCas9.
- the guide RNA in which the transversion mutation occurred comprises at least one nucleotide sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 9, and SEQ ID NO: 13 it may be
- the guide RNA may detect one or more cancer-related mutations selected from the group consisting of EGFR, MET, KRAS, PIK3CA, and BRAF.
- the guide RNA when detecting the EGFR mutation, should include any one or more nucleotide sequences selected from the group consisting of SEQ ID NOs: 1 to 4, 8, 9, and 11 to 13 can
- the guide RNA when detecting the MET mutation, may include one or more nucleotide sequences selected from the group consisting of SEQ ID NOs: 5 to 7.
- the guide RNA when detecting the KRAS mutation, may include the nucleotide sequence of SEQ ID NO: 10.
- the guide RNA when detecting the PIK3CA mutation, may include one or more nucleotide sequences selected from the group consisting of SEQ ID NOs: 14 to 16.
- the guide RNA when detecting the BRAF mutation, may include the nucleotide sequence of SEQ ID NO: 17.
- the present invention can provide a CRISPR/Cas9 guide RNA comprising any one or more nucleotide sequences selected from the group consisting of SEQ ID NOs: 1 to 17.
- the guide RNA may cleave wild-type cell-free DNA.
- the guide RNA is a conversion mutation in any one or more regions selected from the group consisting of a trunk region, a semi-seed region, and a seed region of the guide RNA (transversion mutation) may have occurred.
- the present invention may also provide a composition for diagnosing or predicting prognosis of cancer containing the guide RNA.
- the cancer may be any one or more cancers selected from the group consisting of lung cancer, pancreatic cancer, colon cancer, stomach cancer, breast cancer, kidney cancer, liver cancer, blood cancer, bladder cancer and uterine cancer, but EGFR , cancers caused by MET, KRAS, PIK3CA or BRAF mutations may be applicable without limitation.
- the present invention may also provide a kit for diagnosing cancer or predicting prognosis containing the composition.
- kits may consist of one or more other component compositions, solutions or devices suitable for commonly used expression level analysis methods.
- a kit for measuring protein expression levels may include a substrate, an appropriate buffer, a secondary antibody labeled with a chromogenic enzyme or a fluorescent substance, a chromogenic substrate, and the like for immunological detection of the antibody.
- the kit of the present invention may include a sample extraction means for obtaining a sample from an evaluation subject.
- the sample extraction means may include a needle or a syringe.
- a kit may include a sample collection container for receiving an extracted sample, which may be liquid, gaseous or semi-solid. Kits may further include instructions for use.
- the sample may be any body sample in which an oncogenic mutant gene may be present or secreted.
- the sample may be urine, feces, hair, sweat, saliva, bodily fluid, blood, cells or tissue. Measurement of oncogenic mutant genes in body samples can be performed on whole samples or processed samples.
- the present invention may also provide a method for providing information for diagnosing cancer or predicting prognosis, comprising the step of processing a patient's sample with the guide RNA of claim 1.
- the sample may be urine, feces, hair, sweat, saliva, body fluid, blood, cells or tissues.
- Figure 1 shows disease progression and options for drug therapy or systemic chemotherapy for patients with non-squamous (adenocarcinoma; EGFR-TK, ALK or ROS-1 positive) carcinoma and non-small cell carcinoma NICE for lung cancer Indicates a summary with guidelines.
- non-squamous (adenocarcinoma; EGFR-TK, ALK or ROS-1 positive) carcinoma and non-small cell carcinoma NICE for lung cancer Indicates a summary with guidelines.
- Figure 2 shows a schematic for amplifying mutant alleles in cell-free DNA (cfDNA) using Cas9-sgRNA.
- 3A and 3B show a guide RNA design strategy to amplify all possible mutant alleles with Cas9 treatment in cell-free DNA (cfDNA).
- 4a and 4b show an in vitro cleavage assay for detecting a KRAS mutant (c.35G>C) sequence using the guide RNA of the present invention and the results thereof.
- FIG. 5 shows an in vitro cleavage assay for detecting an EGFR mutation (c.2369C>T or p.T790M) sequence using the guide RNA of the present invention and the results thereof.
- 6a and 6b show an in vitro cleavage assay for detecting an EGFR mutation (c.2573 T>G or p.L858R) sequence using the guide RNA of the present invention and the result thereof.
- Figure 7 is an in vitro cleavage assay for detecting the EGFR mutation (c.2573 T>G or p.L858R) sequence in a patient (LA-29) sample using the guide RNA of the present invention and the result indicates
- Figure 8 is an in vitro detection of EGFR mutation (p.C7975, L718Q or p.(729_761) loss) or MET mutation (c.2888, c.3028 or 'TAC'Y1003X) sequence using the guide RNA of the present invention.
- the cleavage assay in vitro cleavage assay and its results are shown.
- FIG. 10 shows the PCR results of detecting the EGFR mutation (T790M) sequence using the guide RNA of the present invention.
- Figure 11 quantitatively shows the PCR results of detecting the EGFR mutation (T790M) sequence using the guide RNA of the present invention.
- 17 shows PCR results for mutant genes using the guide RNA of the present invention based on a cfDNA reference standard set.
- FIG. 19 shows the results of detecting the L858R mutation among the EGFR mutations in patient (LA-29, LA-209 or LA-292) samples using the guide RNA and Cas9 of the present invention.
- Figure 21 shows the results of multiple detection of the T790M or E19del mutation among EGFR mutations in a patient (LA-232) sample using the guide RNA and Cas9 of the present invention.
- Figure 22 shows the results of single detection of the T790M or E19del mutation among EGFR mutations in a patient (LA-322) sample using the guide RNA and Cas9 of the present invention.
- Figure 23 shows the results of multiplex detection of the T790M or E19del mutation among EGFR mutations in a patient (LA-322) sample using the guide RNA and Cas9 of the present invention.
- Wild-type and mutant target sequences of selected genes and guide RNA sequences were prepared for testing in vitro transcription cleavage (IVT) analysis.
- GAAATGGTTTCAAATGAATCTGTAGAC tac CGAGCTACTTT (SEQ ID NO: 27) AAATGAATCTGTAGAC tac C GAG EGFR (L718Q or c.2153 T> A) WT-T GAATTCAAAAAGATCAAAGTGC t GGGCTCCGGTGCGTTCGG (SEQ ID NO: 28) AAGATCAAAGTGC t GGGCTC CGG (SEQ ID NO: 8) Wild sgRNAs Mut-A GAATTCAAAAAGATCAAAGTGC a GGGCTCCGGTGCGTTCGG (SEQ ID NO: 29) AAGATCA c AGTGC t GGGCTC CGG (SEQ ID NO: 9) Transversion sgRNAs KRAS (c.35G) WT-G TGACTGAATATAAACTTGTGGTAGTTGGAGCTG g TGGCGTAGGCA (SEQ ID NO: 30) AAACTTGTGGTAGTTGGAGC TGG (SEQ ID NO:
- [Table 1] shows guide RNAs for drug resistance mutations.
- Both wild-type and mutant target sequences of selected genes for testing in vitro transcription cleavage (IVT) analysis were subcloned into a T-blunt cloning vector for IVT testing, the positions of mutations in the wild-type target sequences are highlighted in bold and the corresponding nucleotides Mutations are shown in red (lower case).
- Mutational '?' Marking means any nucleotide that is not a wild-type nucleotide.
- Small guide RNAs for each target were designed and the PAM sequences are shown in blue (italic). Transversion mutations are shown in green. After confirming the IVT analysis, the samples were PCR amplified and analyzed through NGS.
- sgRNAs were designed to target 20 nucleotides together with the PAM site, but were disrupted by oncogenic mutations (c.35G>C) in the case of KRAS mutations (PAM).
- PAM KRAS mutations
- IVTT in vitro cleavage assay
- target sequences were subcloned into T-blunt cloning vectors (wild-type and mutant KRAS sequences) and the plasmids were linearized with the vector's restriction enzymes.
- the linearized product was further cleaved by treatment with Cas9 nuclease and wild type sequence specific sgRNA.
- the sgRNA was designed to target a sequence of 20 nucleotides with the PAM site, but for EGFR mutations (c.2369C>T or p.T790M), the target mutation site is the trunk of the sgRNA binding site. (trunk) is found within the area.
- This activity of wild-type targeting sgRNA can also cleave mutant target alleles in cell-free DNA.
- TmWT sgRNA transversion mutation in the trunk region of the sgRNA.
- This TmWT-sgRNA is neither recognized nor cleaved by the Cas9 nuclease at the mutant allele because of its low resistance to both mutations.
- target sequences were subcloned into a T-blunt cloning vector (wild-type and mutant EGFR sequences) and the plasmid was linearized with the vector's restriction enzymes.
- Linearized products were further cleaved by treatment with different combinations of Cas9 nuclease variants with wild type sequence specific sgRNA (WT sgRNA) and inversion mutant sgRNA (TmWT sgRNA). After electrophoresis of wild-type or mutant DNA on a 0.8% gel, linearized fragments (uncleaved) and cleaved fragments (cleaved) were separated by size and indicated by red arrows. The DNA targeted in the wild type was completely cleaved by the Cas9 variant with WT-sgRNA and even with the mutant target sequence by Cas9 and WT-sgRNA.
- WT sgRNA wild type sequence specific sgRNA
- TmWT sgRNA inversion mutant sgRNA
- the sgRNA (TmWT-sgRNA) in the transmutation mutant showed different cleavage patterns for Cas9 variants. This indicates that the TmWT-sgRNA is low resistant to both mutations and cannot completely cleave the mutation target allele.
- the wild-type target allele was excised and removed to generate the mutant allele (EGFR mutation (c.2369C>T or p.T790M; c.2573 T>G or p.L858R; p.C797S, L718Q or p.(729_761) deletion), MET mutation (c.2888, c.3028 or 'TAC'Y1003X), BRAF mutation (p.V600E or c.1799T>A) or PIK3CA mutation (c.1624G>A or p. E542K; p.H1047? or c.3140A>?)) could be enriched (Figs. 5 to 11).
- transversion mutant sgRNA was not designed because the mutation site was in the seed region.
- the fold increase of the target sequence was compared to the fold increase of the untreated control product.
- the amount of EGFR target region relative to the untreated control product in each lane was calculated by NGS analysis.
- the plasmid mixture in the presence of the mutant plasmid was subjected to CUT-PCR after (orange or pink bars) or without (purple or blue bars) targeted deep sequencing was performed. It was originally mixed with the wild-type plasmid at a ratio of 0.5 to 5%.
- the resulting PCR amplicons were subjected to paired-end sequencing with MiSeq.
- NGS results were analyzed for wild-type and mutant sequence fold change for all mixing ratios of mutant DNA fragments in both Cas9 and eCas9 variants compared with TmWT-sgRNA.
- the multiplex cfDNA standard sample contained 4 genes with 8 different mutations and included 3 proportions of each gene (FIG. 16).
- the mixed sgRNA was treated with KRAS, EGFR-T790M or EGFR 729-761bp deletion samples, and then the results of in vitro cleavage assay were performed are shown in [Table 2].
- Mutation targets in cell-free DNA were detected using the guide RNA of the present invention in the blood of lung cancer patients with mutations (FIG. 18).
- Table 3 below shows patient samples with the L858R mutation
- Table 4 shows patient samples with the T790M and E19del mutations.
- SEQ ID NO: 1 is a wild-type guide RNA (wild sgRNA) capable of detecting EGFR (p.T790M or c.2369C>T) mutation, and SEQ ID NO: 18 can be used as a target sequence when used for in vitro cleavage analysis.
- wild sgRNA wild-type guide RNA
- SEQ ID NO: 18 can be used as a target sequence when used for in vitro cleavage analysis.
- SEQ ID NO: 2 is a transversion guide RNA (transversion sgRNA) capable of detecting EGFR (p.T790M or c.2390 G>C) mutation, and SEQ ID NO: 19 can be used as a target sequence when used for in vitro cleavage analysis have.
- transversion guide RNA comprising the nucleotide sequence of SEQ ID NO: 2
- the mutant sequence can be amplified by 1% to 32%.
- SEQ ID NO: 3 is a wild-type guide RNA (wild sgRNA) capable of detecting EGFR (p.C797S) mutation, and SEQ ID NO: 20 can be used as a target sequence when used for in vitro cleavage analysis.
- wild sgRNA wild-type guide RNA
- SEQ ID NO: 20 can be used as a target sequence when used for in vitro cleavage analysis.
- SEQ ID NO: 4 is a transversion guide RNA (transversion sgRNA) capable of detecting EGFR (p.C797S) mutation, and SEQ ID NO: 21 can be used as a target sequence when used for in vitro cleavage analysis.
- transversion guide RNA transversion sgRNA
- SEQ ID NO: 21 can be used as a target sequence when used for in vitro cleavage analysis.
- the mutant sequence can be amplified by 1% to 13%.
- SEQ ID NO: 5 is a wild-type guide RNA (wild sgRNA) capable of detecting MET c.2888 Int13-Exon14 Acceptor (Exon-14 Skipping) mutation, and SEQ ID NO: 22 or 23 is used as a target sequence when used for in vitro cleavage analysis. can do.
- wild sgRNA wild-type guide RNA
- SEQ ID NO: 22 or 23 is used as a target sequence when used for in vitro cleavage analysis. can do.
- SEQ ID NO: 6 is a wild-type guide RNA (wild sgRNA) capable of detecting MET c.3028 Exon14-Int14 Donor (Exon-14 Skipping) mutation, and SEQ ID NO: 24 or 25 is used as a target sequence when used for in vitro cleavage analysis. can do.
- wild sgRNA wild-type guide RNA
- SEQ ID NO: 24 or 25 is used as a target sequence when used for in vitro cleavage analysis. can do.
- SEQ ID NO: 7 is a wild-type guide RNA (wild sgRNA) capable of detecting MET 'TAC' Y1003X (Exon-14 Skipping) mutation, and SEQ ID NO: 26 or 27 can be used as a target sequence when used for in vitro cleavage analysis .
- wild sgRNA wild-type guide RNA
- SEQ ID NO: 26 or 27 can be used as a target sequence when used for in vitro cleavage analysis .
- SEQ ID NO: 8 is a wild-type guide RNA (wild sgRNA) capable of detecting EGFR (L718Q or c.2153 T> A) mutation, and SEQ ID NO: 28 can be used as a target sequence when used for in vitro cleavage analysis.
- wild sgRNA wild-type guide RNA
- SEQ ID NO: 28 can be used as a target sequence when used for in vitro cleavage analysis.
- SEQ ID NO: 9 is a transversion guide RNA (transversion sgRNA) capable of detecting EGFR (L718Q) mutation, and SEQ ID NO: 29 can be used as a target sequence when used for in vitro cleavage analysis.
- transversion guide RNA transversion sgRNA
- SEQ ID NO: 29 can be used as a target sequence when used for in vitro cleavage analysis.
- the mutant sequence can be amplified from 0.8% to 23.7%.
- SEQ ID NO: 10 is a wild-type guide RNA (wild sgRNA) capable of detecting KRAS (c.35G) mutation, and SEQ ID NO: 30 or 31 can be used as a target sequence when used for in vitro cleavage analysis.
- wild sgRNA wild-type guide RNA
- SEQ ID NO: 30 or 31 can be used as a target sequence when used for in vitro cleavage analysis.
- the mutant sequence can be amplified by 1.5% to 50%.
- SEQ ID NO: 11 is a wild-type guide RNA (wild sgRNA) capable of detecting EGFR, 15bp Del p. (729_761) mutation, and SEQ ID NO: 32 or 33 can be used as a target sequence when used for in vitro cleavage analysis.
- wild sgRNA wild-type guide RNA
- SEQ ID NO: 32 or 33 can be used as a target sequence when used for in vitro cleavage analysis.
- the mutant sequence can be amplified from 0.5% to 23%.
- SEQ ID NO: 12 is a wild-type guide RNA (wild sgRNA) capable of detecting EGFR (p.L858R or c.2573 T>G) mutation, and SEQ ID NO: 34 can be used as a target sequence when used for in vitro cleavage analysis. .
- wild sgRNA wild-type guide RNA
- SEQ ID NO: 34 can be used as a target sequence when used for in vitro cleavage analysis.
- SEQ ID NO: 13 is a transversion guide RNA (transversion sgRNA) capable of detecting EGFR (p.L858R) mutation, and SEQ ID NO: 35 can be used as a target sequence when used for in vitro cleavage analysis.
- transversion sgRNA transversion guide RNA
- SEQ ID NO: 35 can be used as a target sequence when used for in vitro cleavage analysis.
- the mutant sequence can be amplified from 1.7% to 63%.
- SEQ ID NO: 14 is a wild-type guide RNA (wild sgRNA) capable of detecting PIK3CA (p.E542K or c.1624G>A) mutation, and SEQ ID NO: 36 or 37 can be used as a target sequence when used for in vitro cleavage analysis have.
- wild sgRNA wild-type guide RNA
- PIK3CA p.E542K or c.1624G>A
- SEQ ID NO: 15 is a wild-type guide RNA (wild sgRNA) capable of detecting PIK3CA (p.E545? or c.1633G>?) mutation, and SEQ ID NO: 38 or 39 can be used as a target sequence when used for in vitro cleavage analysis.
- wild sgRNA wild-type guide RNA
- SEQ ID NO: 38 or 39 can be used as a target sequence when used for in vitro cleavage analysis.
- SEQ ID NO: 16 is a wild-type guide RNA (wild sgRNA) capable of detecting PIK3CA (p.H1047? or c.3140A>?) mutation, and SEQ ID NO: 40 or 41 can be used as a target sequence when used for in vitro cleavage analysis.
- wild sgRNA wild-type guide RNA
- SEQ ID NO: 40 or 41 can be used as a target sequence when used for in vitro cleavage analysis.
- SEQ ID NO: 17 is a wild-type guide RNA (wild sgRNA) capable of detecting PIK3CA (p.V600E or c.1799T>A) mutation, and SEQ ID NO: 42 or 43 can be used as a target sequence when used for in vitro cleavage analysis have.
- wild sgRNA wild-type guide RNA
- SEQ ID NO: 42 or 43 can be used as a target sequence when used for in vitro cleavage analysis have.
- SEQ ID NO: 18 represents a target sequence of wild-type guide RNA (wild sgRNA) of SEQ ID NO: 1 capable of detecting EGFR (p.T790M or c.2369C>T) mutation.
- SEQ ID NO: 19 represents a target sequence of the transversion guide RNA (transversion sgRNA) of SEQ ID NO: 2 capable of detecting EGFR (p.T790M or c.2390 G>C) mutation.
- transversion guide RNA transversion sgRNA
- SEQ ID NO: 20 represents a target sequence of wild-type guide RNA (wild sgRNA) of SEQ ID NO: 3 capable of detecting EGFR (p.C797S) mutation.
- SEQ ID NO: 21 represents a target sequence of the conversion mutation guide RNA (transversion sgRNA) of SEQ ID NO: 4 capable of detecting EGFR (p.C797S) mutation.
- conversion sgRNA conversion sgRNA
- SEQ ID NO: 22 represents a target sequence of wild-type guide RNA (wild sgRNA) of SEQ ID NO: 5 capable of detecting MET c.2888 Int13-Exon14 Acceptor (Exon-14 Skipping) mutation.
- SEQ ID NO: 23 represents a target sequence of wild-type guide RNA (wild sgRNA) of SEQ ID NO: 5 capable of detecting MET c.2888 Int13-Exon14 Acceptor (Exon-14 Skipping) mutation.
- SEQ ID NO: 24 represents a target sequence of wild-type guide RNA (wild sgRNA) of SEQ ID NO: 6 capable of detecting MET c.3028 Exon14-Int14 Donor (Exon-14 Skipping) mutation.
- SEQ ID NO: 25 represents a target sequence of wild-type guide RNA (wild sgRNA) of SEQ ID NO: 6 capable of detecting MET c.3028 Exon14-Int14 Donor (Exon-14 Skipping) mutation.
- SEQ ID NO: 26 represents a target sequence of wild-type guide RNA (wild sgRNA) of SEQ ID NO: 7 capable of detecting MET 'TAC' Y1003X (Exon-14 Skipping) mutation.
- SEQ ID NO: 27 represents a target sequence of wild-type guide RNA (wild sgRNA) of SEQ ID NO: 7 capable of detecting MET 'TAC' Y1003X (Exon-14 Skipping) mutation.
- SEQ ID NO: 28 represents a target sequence of wild-type guide RNA (wild sgRNA) of SEQ ID NO: 8 capable of detecting EGFR (L718Q or c.2153 T> A) mutation.
- SEQ ID NO: 29 represents a target sequence of the conversion mutation guide RNA (transversion sgRNA) of SEQ ID NO: 9 capable of detecting EGFR (L718Q) mutation.
- conversion sgRNA conversion sgRNA
- SEQ ID NO: 30 represents a target sequence of wild-type guide RNA (wild sgRNA) of SEQ ID NO: 10 capable of detecting KRAS (c.35G) mutation.
- SEQ ID NO: 31 represents a target sequence of wild-type guide RNA (wild sgRNA) of SEQ ID NO: 10 capable of detecting KRAS (c.35G) mutation.
- SEQ ID NO: 32 represents a target sequence of wild-type guide RNA (wild sgRNA) of SEQ ID NO: 11 capable of detecting EGFR, 15 bp Del p. (729_761) mutation.
- SEQ ID NO: 33 represents a target sequence of wild-type guide RNA (wild sgRNA) of SEQ ID NO: 11 capable of detecting EGFR, 15 bp Del p. (729_761) mutation.
- SEQ ID NO: 34 represents a target sequence of wild-type guide RNA (wild sgRNA) of SEQ ID NO: 12 capable of detecting EGFR (p.L858R or c.2573 T>G) mutation.
- SEQ ID NO: 35 represents a target sequence of the transversion guide RNA (transversion sgRNA) of SEQ ID NO: 13 capable of detecting EGFR (p.L858R) mutation.
- SEQ ID NO: 36 represents a target sequence of wild-type guide RNA (wild sgRNA) of SEQ ID NO: 14 capable of detecting PIK3CA (p.E542K or c.1624G>A) mutation.
- SEQ ID NO: 37 represents a target sequence of wild-type guide RNA (wild sgRNA) of SEQ ID NO: 14 capable of detecting PIK3CA (p.E542K or c.1624G>A) mutation.
- SEQ ID NO: 38 represents a target sequence of wild-type guide RNA (wild sgRNA) of SEQ ID NO: 15 capable of detecting PIK3CA (p.E545? or c.1633G>?) mutation.
- SEQ ID NO: 39 represents a target sequence of wild-type guide RNA (wild sgRNA) of SEQ ID NO: 15 capable of detecting PIK3CA (p.E545? or c.1633G>?) mutation.
- SEQ ID NO: 40 represents a target sequence of wild-type guide RNA (wild sgRNA) of SEQ ID NO: 16 capable of detecting PIK3CA (p.H1047? or c.3140A>?) mutation.
- SEQ ID NO: 41 represents a target sequence of wild-type guide RNA (wild sgRNA) of SEQ ID NO: 16 capable of detecting PIK3CA (p.H1047? or c.3140A>?) mutation.
- SEQ ID NO: 42 represents a target sequence of wild-type guide RNA (wild sgRNA) of SEQ ID NO: 17 capable of detecting PIK3CA (p.V600E or c.1799T>A) mutation.
- SEQ ID NO: 43 represents a target sequence of wild-type guide RNA (wild sgRNA) of SEQ ID NO: 17 capable of detecting PIK3CA (p.V600E or c.1799T>A) mutation.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
유전자/
Mut.AA |
뉴클레오타이드 (WT/Mut) | In-vitro Cleavage Assay 타겟 서열 | sgRNA + PAM 서열 | sgRNA 유형 |
EGFR (p.T790M or c.2369C> T) | WT - C | TCACCTCCACCGTGCAGCTCATCAcGCAGCTCATGCCCTTC (서열번호 18) | CTGCgTGATGAGCTGCACGG TGG (서열번호 1) | Wild sgRNA |
Mut - T | TCACCTCCACCGTGCAGCTCATCAtGCAGCTCATGCCCTTC (서열번호 19) | CTGCgTGcTGAGCTGCACGG TGG (서열번호 2) | Transversion sgRNA | |
EGFR (p.C797S or c.2390 G> C) | WT - G | ACGCAGCTCATGCCCTTCGGCTgCCTCCTGGACTATGTCCG (서열번호 20) | CATGCCCTTCGGCTgCCTCC TGG (서열번호 3) | Wild sgRNA |
Mut - C | ACGCAGCTCATGCCCTTCGGCTcCCTCCTGGACTATGTCCG (서열번호 21) | CATGCaCTTCGGCTgCCTCC TGG (서열번호 4) | Transversion sgRNA | |
MET c.2888 Int13-Exon14 Acceptor (Exon-14 Skipping) | WT - GA | TTAACAAGCTCTTTCTTTCTCTCTGTTTTAAgaTCTGGGCA (서열번호 22) | TTTCTCTCTGTTTTAAgaTC TGG (서열번호 5) | Wild sgRNA |
Mut - ?? | TTAACAAGCTCTTTCTTTCTCTCTGTTTTAAgaTCTGGGCA (서열번호 23) | TTTCTCTCTGTTTTAAgaTC TGG | ||
MET c.3028 Exon14-Int14 Donor (Exon-14 Skipping) | WT - AC | ATTTCTCAGAACAATAAACTGAAATATacCTTCTGGAAAAG (서열번호 24) | ATAAACTGAAATATacCTTC TGG (서열번호 6) | Wild sgRNA |
Mut - ?? | ATTTCTCAGAACAATAAACTGAAATATacCTTCTGGAAAAG (서열번호 25) | ATAAACTGAAATATacCTTC TGG | ||
MET 'TAC' Y1003X (Exon-14 Skipping) |
WT - TAC | GAAATGGTTTCAAATGAATCTGTAGACtacCGAGCTACTTT (서열번호 26) | AAATGAATCTGTAGACtacC GAG (서열번호 7) | Wild sgRNA |
Mut - ??? | GAAATGGTTTCAAATGAATCTGTAGACtacCGAGCTACTTT (서열번호 27) | AAATGAATCTGTAGACtacC GAG | ||
EGFR (L718Q or c.2153 T> A) | WT - T | GAATTCAAAAAGATCAAAGTGCtGGGCTCCGGTGCGTTCGG (서열번호 28) | AAGATCAAAGTGCtGGGCTC CGG (서열번호 8) | Wild sgRNA |
Mut - A | GAATTCAAAAAGATCAAAGTGCaGGGCTCCGGTGCGTTCGG (서열번호 29) | AAGATCAcAGTGCtGGGCTC CGG (서열번호 9) | Transversion sgRNA | |
KRAS (c.35G) | WT - G | TGACTGAATATAAACTTGTGGTAGTTGGAGCTGgTGGCGTAGGCA (서열번호 30) | AAACTTGTGGTAGTTGGAGC TGG (서열번호 10) | Wild sgRNA |
Mut - C (A or T) | TGACTGAATATAAACTTGTGGTAGTTGGAGCTGcTGGCGTAGGCA (서열번호 31) | AAACTTGTGGTAGTTGGAGC TGg | ||
EGFR, 15bp Del p.(729_761) | WT - GGAATTAAGAGAAGC | AAGTTAAAATTCCCGTCGCTATCAAggaattaagagaagcAACATC (서열번호 32) | TAAAATTCCCGTCGCTATCA AGG (서열번호 11) | Wild sgRNA |
Mut - 15bp Deletion | AAGTTAAAATTCCCGTCGCTATCAAggaattaagagaagcAACATC (서열번호 33 | TAAAATTCCCGTCGCTATCA AGG | ||
EGFR (p.L858R or c.2573 T>G) | WT - T | GATCACAGATTTTGGGCtGGCCAAACTGCTGGGTGCGGAAG (서열번호 34) | TTTTGGGCtGGCCAAACTGC TGG (서열번호 12) | Wild sgRNA |
Mut - G | GATCACAGATTTTGGGCgGGCCAAACTGCTGGGTGCGGAAG (서열번호 35) | TTTTGtGCtGGCCAAACTGC TGG (서열번호 13) | Transversion sgRNA | |
PIK3CA p.E542K or c.1624G>A | WT - G | CACGAGATCCTCTCTCTgAAATCACTGAGCAGGAGAAAG (서열번호 36) | TGCTCAGTGATTTcAGAGAG AGG (서열번호 14) | Wild sgRNA |
Mut - A | CACGAGATCCTCTCTCTaAAATCACTGAGCAGGAGAAAG (서열번호 37) | TGCTCAGTGATTTcAGAGAG AGG | ||
PIK3CA p.E545? or c.1633G>? | WT - G | CACGAGATCCTCTCTCTGAAATCACTgAGCAGGAGAAAG (서열번호 38) | TCTCTCTGAAATCACTgAGC AGG (서열번호 15) | Wild sgRNA |
Mut - ?? (A or C or T) | CACGAGATCCTCTCTCTGAAATCACTaAGCAGGAGAAAG (서열번호 39) | TCTCTCTGAAATCACTgAGC AGG | ||
PIK3CA p.H1047? or c.3140A>? | WT - T | CATGAAACAAATGAATGATGCACaTCATGGTGGCTGG (서열번호 40) | CAAATGAATGATGCACaTCA TGG (서열번호 16) | Wild sgRNA |
Mut - ?? (G or C or T) | CATGAAACAAATGAATGATGCACgTCATGGTGGCTGG (서열번호 41) | CAAATGAATGATGCACaTCA TGG | ||
BRAF p.V600E or c.1799T>A | WT - T | GATTTTGGTCTAGCTACAGtGAAATCTCGATGGAGTGGG (서열번호 42) | TAGCTACAGtGAAATCTCGA TGG (서열번호 17) | Wild sgRNA |
Mut - A | GATTTTGGTCTAGCTACAGaGAAATCTCGATGGAGTGGG (서열번호 43) | TAGCTACAGtGAAATCTCGA TGG |
Cas9 with Mixed-sgRNA's Treated for Multiplex 1 | KRAS PCR | EGFR T790M PCR | EGFR Deletion PCR | |||||||||
0.1 | 1 | 5 | 100 | 0.1 | 1 | 5 | 100 | 0.1 | 1 | 5 | 100 | |
Cas9 Not Treated | 0.10 | 1.71 | 7.77 | 0.05 | 0.34 | 1.24 | 5.79 | 0.17 | 0.04 | 0.94 | 5.53 | 0.05 |
Cas9 Treated | 2.33 | 9.91 | 4.12 | 0.09 | 0.05 | 0.02 | 7.92 | 0.05 | 4.59 | 0.02 | 25.96 | 0.27 |
Fold Change(mut Seq Enreached) | 22.28 | 5.81 | 0.53 | 1.87 | 0.14 | 0.02 | 1.37 | 0.32 | 102.34 | 0.02 | 4.69 | 5.86 |
ID | 날짜 | 성별 | 구분 |
LA-29 | 2015-06-19 | 남 | 말기 |
LA-209 | 2016-10-04 | 여 | 후기 |
LA-292 | 2019-04-19 | 남 | 후기 |
ID | 날짜 | 성별 | 구분 |
LA-232 | 2017-02-14 | 남 | 후기 |
LA-322 | 2019-10-07 | 남 | 후기 |
LA-323 | 2019-10-14 | 여 | 후기 |
Claims (17)
- CRISPR/Cas9 시스템에 이용되는 가이드 RNA(guide RNA) 로서,상기 가이드 RNA 는 야생형 무 세포 DNA 를 절단하는 것을 특징으로 하는 가이드 RNA.
- 제1항에 있어서, 상기 가이드 RNA는 서열번호 1 내지 17 로 이루어진 군에서 선택되는 어느 하나 이상의 뉴클레오타이드 서열을 포함하는 것을 특징으로 하는 가이드 RNA.
- 제1항에 있어서, 상기 가이드 RNA 는 가이드 RNA 의 트렁크(trunk) 영역, 세미 시드(semi-seed) 영역 및 시드(seed) 영역으로 이루어진 군에서 선택되는 어느 하나 이상의 영역에서 전환 돌연변이(transversion mutation) 가 발생한 것을 특징으로 하는 가이드 RNA.
- 제3항에 있어서, 상기 가이드 RNA 는 서열번호 2, 서열번호 4, 서열번호 9 및 서열번호 13 으로 이루어진 군에서 선택되는 어느 하나 이상의 뉴클레오타이드 서열을 포함하는 것을 특징으로 하는 가이드 RNA.
- 제1항에 있어서, 상기 가이드 RNA 는 EGFR, MET, KRAS, PIK3CA 및 BRAF 로 이루어진 군에서 선택되는 어느 하나 이상의 암 관련 돌연변이를 검출할 수 있는 것을 특징으로 하는 가이드 RNA.
- 제5항에 있어서, 상기 EGFR 돌연변이를 검출하는 경우, 상기 가이드 RNA 는 서열번호 1 내지 4, 8, 9 및 11 내지 13 으로 이루어진 군에서 선택되는 어느 하나 이상의 뉴클레오타이드 서열을 포함하는 것을 특징으로 하는 가이드 RNA.
- 제5항에 있어서, 상기 MET 돌연변이를 검출하는 경우, 상기 가이드 RNA 는 서열번호 5 내지 7 로 이루어진 군에서 선택되는 어느 하나 이상의 뉴클레오타이드 서열을 포함하는 것을 특징으로 하는 가이드 RNA.
- 제5항에 있어서, 상기 KRAS 돌연변이를 검출하는 경우, 상기 가이드 RNA 는 서열번호 10 의 뉴클레오타이드 서열을 포함하는 것을 특징으로 하는 가이드 RNA.
- 제5항에 있어서, 상기 PIK3CA 돌연변이를 검출하는 경우, 상기 가이드 RNA 는 서열번호 14 내지 16 으로 이루어진 군에서 선택되는 어느 하나 이상의 뉴클레오타이드 서열을 포함하는 것을 특징으로 하는 가이드 RNA.
- 제5항에 있어서, 상기 BRAF 돌연변이를 검출하는 경우, 상기 가이드 RNA 는 서열번호 17 의 뉴클레오타이드 서열을 포함하는 것을 특징으로 하는 가이드 RNA.
- 서열번호 1 내지 17 로 이루어진 군에서 선택되는 어느 하나 이상의 뉴클레오타이드 서열을 포함하는 CRISPR/Cas9 의 가이드 RNA 를 포함하는 암 진단 또는 예후 예측용 조성물.
- 제11항에 있어서, 상기 가이드 RNA 는 가이드 RNA 의 트렁크(trunk) 영역, 세미 시드(semi-seed) 영역 및 시드(seed) 영역으로 이루어진 군에서 선택되는 어느 하나 이상의 영역에서 전환 돌연변이(transversion mutation) 가 발생한 것을 특징으로 하는 조성물.
- 제11항에 있어서, 상기 가이드 RNA 는 EGFR, MET, KRAS, PIK3CA 및 BRAF 로 이루어진 군에서 선택되는 어느 하나 이상의 암 관련 돌연변이를 검출할 수 있는 것을 특징으로 하는 조성물.
- 제11항에 있어서, 상기 가이드 RNA 는 야생형 무 세포 DNA 를 절단하는 것을 특징으로 하는 조성물.
- 제11항에 있어서, 상기 암은 폐암, 췌장암, 대장암, 위암, 유방암, 신장암, 간암, 혈액암, 방광암 및 자궁암 으로 이루어진 군에서 선택되는 어느 하나 이상의 암인 것을 특징으로 하는 조성물.
- 제11항의 조성물을 포함하는 암 진단 또는 예후 예측용 키트.
- 환자의 시료에 제11항의 조성물을 처리하는 단계를 포함하는 암 진단 또는 예후 예측을 위한 정보제공 방법.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023571114A JP2024517984A (ja) | 2021-05-11 | 2022-05-10 | 発がん突然変異遺伝子検出用ガイドrnaおよびその用途 |
CA3218653A CA3218653A1 (en) | 2021-05-11 | 2022-05-10 | Guide rna for detecting oncogenic mutant gene and use thereof |
EP22807791.3A EP4339285A1 (en) | 2021-05-11 | 2022-05-10 | Guide rna for detecting oncogenic mutant gene and use thereof |
AU2022273481A AU2022273481A1 (en) | 2021-05-11 | 2022-05-10 | Guide rna for detecting oncogenic mutant gene and use thereof |
CN202280034885.XA CN117597445A (zh) | 2021-05-11 | 2022-05-10 | 致癌性突变基因检测用向导rna及其用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210061037A KR102616916B1 (ko) | 2021-05-11 | 2021-05-11 | 발암성 돌연변이 유전자 검출용 가이드 rna 내지 이의 용도 |
KR10-2021-0061037 | 2021-05-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022240143A1 true WO2022240143A1 (ko) | 2022-11-17 |
Family
ID=84028603
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/006665 WO2022240143A1 (ko) | 2021-05-11 | 2022-05-10 | 발암성 돌연변이 유전자 검출용 가이드 rna 내지 이의 용도 |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP4339285A1 (ko) |
JP (1) | JP2024517984A (ko) |
KR (1) | KR102616916B1 (ko) |
CN (1) | CN117597445A (ko) |
AU (1) | AU2022273481A1 (ko) |
CA (1) | CA3218653A1 (ko) |
WO (1) | WO2022240143A1 (ko) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150322457A1 (en) * | 2012-10-23 | 2015-11-12 | Toolgen Incorporated | Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof |
KR20150138075A (ko) * | 2014-05-28 | 2015-12-09 | 주식회사 툴젠 | 불활성화된 표적 특이적 뉴클레아제를 이용한 표적 dna의 분리 방법 |
KR20180041606A (ko) * | 2016-10-14 | 2018-04-24 | 연세대학교 산학협력단 | Kras 유전자에 상보적인 가이드 rna 및 이의 용도 |
KR20190095160A (ko) * | 2018-02-06 | 2019-08-14 | 주식회사 진씨커 | 돌연변이 세포 유리 유전자 분리 키트 및 이를 이용한 돌연변이 세포 유리 유전자 분리 방법 |
KR20190113687A (ko) * | 2018-03-27 | 2019-10-08 | (주)지플러스 생명과학 | 가이드 rna 및 엔도뉴클레아제를 유효성분으로 포함하는 암 치료용 약학적 조성물 |
KR20210061037A (ko) | 2019-11-19 | 2021-05-27 | 히즈케어스 주식회사 | 마비 장애인 일상생활 재활운동 서비스 시스템 |
-
2021
- 2021-05-11 KR KR1020210061037A patent/KR102616916B1/ko active IP Right Grant
-
2022
- 2022-05-10 WO PCT/KR2022/006665 patent/WO2022240143A1/ko active Application Filing
- 2022-05-10 JP JP2023571114A patent/JP2024517984A/ja active Pending
- 2022-05-10 AU AU2022273481A patent/AU2022273481A1/en active Pending
- 2022-05-10 EP EP22807791.3A patent/EP4339285A1/en active Pending
- 2022-05-10 CN CN202280034885.XA patent/CN117597445A/zh active Pending
- 2022-05-10 CA CA3218653A patent/CA3218653A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150322457A1 (en) * | 2012-10-23 | 2015-11-12 | Toolgen Incorporated | Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof |
KR20150138075A (ko) * | 2014-05-28 | 2015-12-09 | 주식회사 툴젠 | 불활성화된 표적 특이적 뉴클레아제를 이용한 표적 dna의 분리 방법 |
KR20180041606A (ko) * | 2016-10-14 | 2018-04-24 | 연세대학교 산학협력단 | Kras 유전자에 상보적인 가이드 rna 및 이의 용도 |
KR20190095160A (ko) * | 2018-02-06 | 2019-08-14 | 주식회사 진씨커 | 돌연변이 세포 유리 유전자 분리 키트 및 이를 이용한 돌연변이 세포 유리 유전자 분리 방법 |
KR20190113687A (ko) * | 2018-03-27 | 2019-10-08 | (주)지플러스 생명과학 | 가이드 rna 및 엔도뉴클레아제를 유효성분으로 포함하는 암 치료용 약학적 조성물 |
KR20210061037A (ko) | 2019-11-19 | 2021-05-27 | 히즈케어스 주식회사 | 마비 장애인 일상생활 재활운동 서비스 시스템 |
Also Published As
Publication number | Publication date |
---|---|
EP4339285A1 (en) | 2024-03-20 |
JP2024517984A (ja) | 2024-04-23 |
KR20220153436A (ko) | 2022-11-18 |
CA3218653A1 (en) | 2022-11-17 |
CN117597445A (zh) | 2024-02-23 |
KR102616916B1 (ko) | 2023-12-21 |
AU2022273481A1 (en) | 2023-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015183025A1 (ko) | 표적 특이적 뉴클레아제를 이용한 표적 dna의 민감한 검출 방법 | |
WO2016076672A1 (ko) | 유전체에서 유전자 가위의 비표적 위치를 검출하는 방법 | |
WO2016195382A1 (ko) | 바코드 서열을 포함하는 어댑터를 이용한 차세대 염기서열 분석 방법 | |
WO2017122896A1 (ko) | 수산생물전염병 원인바이러스의 판별 및 검출용 유전자 마커,및 이를 이용한 원인바이러스의 판별 및 검출 방법 | |
WO2020027569A1 (ko) | 피부 세포에서 IDE 유전자 프로모터의 CpG 메틸화 변화를 이용한 알츠하이머 질환 진단용 조성물 및 이의 이용 | |
WO2020171573A1 (ko) | 혈중 무세포 dna 기반 간암 치료 예후예측 방법 | |
WO2020096248A1 (ko) | 폐암 조직 내 세포 유래 돌연변이를 검출하기 위한 프로브 제조 및 검출 방법 | |
WO2021075797A2 (ko) | 특정 유전자의 cpg 메틸화 변화를 이용한 간암 진단용 조성물 및 이의 용도 | |
Eberherr et al. | Rescue of STAT3 function in hyper-IgE syndrome using adenine base editing | |
WO2017222248A1 (ko) | 선천성 기능장애 진단용 조성물 및 이의 용도 | |
WO2022240143A1 (ko) | 발암성 돌연변이 유전자 검출용 가이드 rna 내지 이의 용도 | |
WO2022075788A1 (ko) | LINC01798 유전자의 CpG 메틸화 변화를 이용한 대장암, 직장암 또는 대장 선종 진단용 조성물 및 이의 용도 | |
WO2017094941A1 (ko) | 핵산의 혼합물을 포함하는 샘플에서 복제수 변이를 결정하는 방법 | |
WO2021154009A1 (ko) | 특정 유전자의 CpG 메틸화 변화를 이용한 방광암 진단용 조성물 및 이의 용도 | |
WO2022097844A1 (ko) | 유전자 복제수 변이 정보를 이용하여 췌장암 환자의 생존 예후를 예측하는 방법 | |
WO2017007241A1 (ko) | Parp 및 탄키라제 동시 저해제에 대한 감수성 결정 방법 | |
WO2011059285A2 (ko) | 지노타이핑 방법 | |
WO2022216066A1 (ko) | 암 환자의 예후 예측용 바이오마커 및 이의 용도 | |
WO2018194280A1 (ko) | SDC2(Syndecan 2) 유전자의 메틸화 검출방법 | |
WO2022114732A1 (ko) | Pcr 과정 동안 생성되는 가닥들의 정보를 연결하여 하나의 클러스터를 만들고, 생성된 가닥들의 생성 순서를 추적할 수 있는 방법 | |
WO2020204297A1 (ko) | 개인의 전이효소-접근가능한 염색질 시퀀싱 정보를 이용한 암 진단 마커 및 이의 용도 | |
WO2023132626A1 (ko) | 특정 유전자의 cpg 메틸화 변화를 이용한 전립선암 진단용 조성물 및 이의 용도 | |
WO2020096247A1 (ko) | 유방암 조직 내 세포 유래 돌연변이를 검출하기 위한 프로브 제조 및 검출 방법 | |
WO2022039565A1 (ko) | 연령 관련 황반변성 진단용 바이오마커 및 이의 용도 | |
WO2019194640A1 (ko) | 분자 인덱스된 바이설파이트 시퀀싱 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22807791 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3218653 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280034885.X Country of ref document: CN Ref document number: 18560548 Country of ref document: US Ref document number: 2023571114 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022273481 Country of ref document: AU Ref document number: 805587 Country of ref document: NZ Ref document number: AU2022273481 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2022273481 Country of ref document: AU Date of ref document: 20220510 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022807791 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022807791 Country of ref document: EP Effective date: 20231211 |